-
منظمة الحقوق الرقمية تتحدى شرعية أوامر إزالة المحتوى من شرطة دلهي أمام المحكمة العليا
-
Samsung Leads Global DRAM Market as SK Hynix Gains Share
-
South Korea Proposes Fourth Delay of Cryptocurrency Gains Tax to 2029
-
Kakao Details Spinoff Plan to Monetize AI Through KakaoTalk
-
ASIC Fines Mona Museum Owner's Company for Late Financial Report
-
انتهاء فترة الانخفاض في أسعار الإيجار في فانكوفر لأول مرة منذ ثلاث سنوات
-
Business Leaders Criticize Productivity Commission Inquiry Scope
-
Democrats Vow to Probe Trump Business Deals as Midterm Results Narrow
-
Phoenix Public Library to Host Annual Local Author Fair on Nov. 7
-
SCANDIC FINANCE ने एलेक्स बोडी को समूह का उपाध्यक्ष नियुक्त किया
-
SCANDIC FINANCE แต่งตั้งอเล็กซ์ โบดี เป็นรองประธานกลุ่มบริษัท
-
SCANDIC FINANCE Grubu, Alex Bodi’yi başkan yardımcılığına atadı
-
تطبيق شروط العمل على ميديكيد وخفض تمويل شرائط فحص الفنتانيل
-
حديقة «المطبخ المفتوح» للنحت في فيلادلفيا تجمع المجتمع عبر الفن والطعام
-
Alex Bodi wiceprezesem grupy SCANDIC FINANCE
-
بيكيتوب تطلق خطة طوارئ لتفريغ مخلفات جوهانسبرغ بعد إضراب النقابة
-
Алекс Боди е назначен за вицепрезидент на групата SCANDIC FINANCE
-
Alex Bodi a SCANDIC FINANCE vállalatcsoport új alelnöke
-
Ο Άλεξ Μπόντι νέος αντιπρόεδρος του ομίλου SCANDIC FINANCE
-
Alex Bodi byl jmenován viceprezidentem skupiny SCANDIC FINANCE
-
Alex Bodi utsedd till vicepresident för SCANDIC FINANCE-koncernen
-
تعيين أليكس بودي نائبًا لرئيس مجموعة SCANDIC FINANCE
-
SCANDIC FINANCEグループ、アレックス・ボディ氏を副社長に任命
-
بدء تجديد التسجيل في مدارس ريو دي جانيرو الحكومية للعام الدراسي 2027
-
SCANDIC FINANCE 그룹, 알렉스 보디 부사장 선임
-
تفجع لندن بوفاة اللاعب إيزيكيل ويليامز بعد اعتداء في ميلتون كينز
-
亞歷克斯・博迪獲任命為 SCANDIC FINANCE 集團副總裁
-
Алекса Боді призначено віцепрезидентом групи SCANDIC FINANCE
-
Алекс Боди назначен вице-президентом группы SCANDIC FINANCE
-
Alex Bodi appointed Vice President of SCANDIC FINANCE GROUP
-
Alex Bodi, numit vicepreședinte al grupului SCANDIC FINANCE
-
اختيار ملك وموكس نيتيروي للكرنفال 2027 في باريتو
-
Elon Musk jokes about moving businesses to space after US midterms
-
West Mercia Police opens 2027 cadet applications to Worcestershire teenagers
-
NHS to test blood screening designed to detect 13 cancers earlier
-
Worcestershire road closures announced for Remembrance Sunday events
-
Democrats near House takeover as voters judge Trump presidency
-
UBC professor describes police call after Galloway remark as act of care
-
Lethbridge submits interest in provincial ground ambulance contract
-
False voting claims spread rapidly during US Election Day
-
Trump Prepares Veto Strategy Amid Congressional Shift
-
The Cat in the Hat expands its stakes to cosmic scale in animated reboot
-
Lettermen co-founder Tony Butala dies at 87
-
Byron Donalds Elected Florida Governor, Becoming First Black Republican in Role
-
Byron Donalds wins Florida governor race and underscores Republican strength
-
James Talarico defeats Ken Paxton in historic Texas Senate result
-
Commentator predicts possible US strike on Iran as regional tensions rise
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
E.Qaddoumi--SF-PST